BioAtla Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-39787 BIOATLA, INC. (Exact Name of Registrant as Specified in its Charter) Registrant’s telephone number, including area code: (858) 558-0708 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Accelerated filer Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of August 10, 2026 the number of shares of the registrant’s common stock outstanding was 1,666,100 and the number of shares of theregistrant’s Class B common stock outstanding was 0. BIOATLA, INC.Quarterly Report on Form 10-Q Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements:1Condensed Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 20251Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) for the three and sixmonths ended June 30, 2026 and 20252Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited) for the three and six months ended June30, 2026 and 20253Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2026 and 20255Notes to Condensed Consolidated Financial Statements (unaudited)6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures28PART II.OTHER INFORMATION29Item 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds80Item 3.Defaults Upon Senior Securities80Item 4.Mine Safety Disclosures80Item 5.Other Information80Item 6.Exhibits81SIGNATURES82 PART I—FINANCIAL INFORMATION BioAtla, Inc.Condensed Consolidated Balance Sheets(in thousands, except par value and share amounts) BioAtla, Inc.Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit)(in thousands, except share amounts) BioAtla, Inc.Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit)(in thousands, except share amounts) BioAtla, Inc.Unaudited Condensed Consolidated Statements of Cash Flows(in thousands) BioAtla, Inc.Notes to Unaudited Condensed Consolidated Financial Statements 1. Organization and Summary of Significant Accounting Policies Organization BioAtla, LLC was formed in Delaware in March 2007 and was converted to a Delaware corporation in July 2020 andrenamed BioAtla, Inc. (the “Company”). BioAtla, Inc. is a single legal entity with one consolidated variable interest entity (“VIE”),BA 3021 SPV LLC (see Note 10). The Company has a proprietary platform for creating biologics, including its conditionally activebiologics (“CAB” or “CABs”). CABs have been designed to be active only under certain conditions found in diseased tissue, whileremaining inactive in normal tissue. The Company has developed several CAB drug candidates through Phase 2 clinical trialsincluding: two CAB antibody drug conjugates (“CAB ADC”), mecbotamab vedotin (BA3011), a CAB ADC targeting AXL, andozuriftamab vedotin (BA3021), a CAB ADC targeting ROR2; and evalstotug (BA3071), a CAB anti-CTLA-4 antibody. TheCompany has an ongoing Phase 1 trial for BA3182 (CAB-EpCAM x CAB-CD3), a CAB bispecific antibody targeting EpCAM. Merger and Related Share Consolidation On March 23, 2026, the Company’s stockho